BIOMAT Database Logo BIOMAT Database Logo

Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events. 1987

L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Padua University School of Medicine, Department of Clinical Medicine, Italy.

To further define the mechanisms responsible for the alpha-interferon (alpha-IFN) efficacy in the treatment of hairy cell leukemia (HCL), experiments were carried out to specify the cytotoxic events taking place following this type of therapy. Although an increased natural killer (NK) activity was demonstrable after alpha-IFN treatment, evidence has been provided that hairy cells were not specifically lysed either by fresh autologous/allogenic NK lymphocytes or by lymphokine activated killer (LAK) cells. This property could not be induced in vitro by alpha-IFN or by interleukin-2 (IL-2). Our data favour the hypothesis that the increase of NK cell activity observed following alpha-IFN therapy has not a direct antineoplastic effect but is likely to be of relevance for a non-specific enhancement of the host immune system. In alpha-IFN treated HCL this latter property may account for the better resistance to infections which usually represents the major cause of mortality in these patients.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007943 Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. Hairy Cell Leukemia,Leukemic Reticuloendotheliosis,Reticuloendotheliosis, Leukemic,Hairy Cell Leukemias,Leukemias, Hairy Cell,Leukemic Reticuloendothelioses,Reticuloendothelioses, Leukemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
June 1988, Leukemia,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
[Alpha interferon treatment in hairy cell leukemia].
January 1992, Nordisk medicin,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
June 1987, Seminars in oncology,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients.
May 2000, European journal of haematology,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Alpha-interferon therapy for Japanese patients with hairy cell leukemia.
August 1988, Leukemia,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
July 1991, Blood,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Antibodies in patients with hairy-cell leukemia receiving alpha-2b interferon.
November 1986, The New England journal of medicine,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
[Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia].
July 1987, Klinische Wochenschrift,
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Alpha interferon in the treatment of hairy cell leukemia.
July 1989, Journal of chemotherapy (Florence, Italy),
L Trentin, and A Ambrosetti, and R Zambello, and C Agostini, and M Masciarelli, and F Vinante, and M Chilosi, and G Pizzolo, and G Cetto, and G Semenzato
Interferon alpha in the treatment of hairy cell leukemia.
April 1986, Cancer,
Copied contents to your clipboard!